View Older Stories View More Recent Stories

Feb 16, 2022 08:00AM New Analysis Demonstrates UPLIZNA® (inebilizumab-cdon) Reduces Severity of Attacks Associated with Neuromyelitis Optica Spectrum Disorder (NMOSD)
Feb 15, 2022 11:02AM Horizon Therapeutics (HZNP) Announces New Post-Marketing Safety Analysis Shows Rate of Hearing-Related Events Associated with TEPEZZA Comparable with Clinical Trial Observations
Feb 15, 2022 11:00AM New Post-Marketing Safety Analysis Shows Rate of Hearing-Related Events Associated with TEPEZZA® (teprotumumab-trbw) Comparable with Clinical Trial Observations
Feb 15, 2022 09:00AM Horizon Therapeutics plc Partners with the Doug the Pug Foundation and Sing Me A Story Foundation to Bring Awareness to Rare Diseases Impacting Children through #RAREis Playlist
Feb 10, 2022 08:00AM Horizon Therapeutics plc Named Title Partner of the Irish Open
Feb 7, 2022 08:00AM Horizon Therapeutics plc to Release Fourth-Quarter and Full-Year 2021 Financial Results and Host Webcast on March 1, 2022
Jan 24, 2022 08:00AM Horizon Therapeutics plc Announces First Patient Enrolled in Phase 2b Pivotal Trial Evaluating HZN-825 for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)
Jan 10, 2022 07:31AM Horizon Therapeutics (HZNP) Submits sNLA for Concomitant Use of KRYSTEXXA Plus Methotrexate for People Living with Uncontrolled Gout
Jan 10, 2022 07:30AM Horizon Therapeutics plc Submits Supplemental Biologics License for the Concomitant Use of KRYSTEXXA® (pegloticase injection) Plus Methotrexate for People Living with Uncontrolled Gout
Jan 6, 2022 08:00AM Horizon Therapeutics plc Announces Significant Expansion of East Coast Research and Development and Technical Operations Capability
Dec 23, 2021 08:00AM Horizon Therapeutics plc to Participate in Upcoming Investor Conferences
Dec 16, 2021 08:02AM Alpine Immune Sciences (ALPN) and Horizon Therapeutics (HZNP) Announce Exclusive License and Collaboration Agreement to Develop Novel Protein-Based Therapies for Autoimmune and Inflammatory Diseases
Dec 16, 2021 08:00AM Alpine Immune Sciences and Horizon Therapeutics plc Announce Exclusive License and Collaboration Agreement to Develop Novel Protein-Based Therapies for Autoimmune and Inflammatory Diseases
Dec 16, 2021 08:00AM Alpine Immune Sciences and Horizon Therapeutics plc Announce Exclusive License and Collaboration Agreement to Develop Novel Protein-Based Therapies for Autoimmune and Inflammatory Diseases
Dec 2, 2021 09:00AM Horizon Therapeutics plc Makes $100,000 Seed Donation to Support Fundraising Efforts to Renovate Emmett Till’s Home into a Museum and Theater
Dec 2, 2021 08:30AM Great Place to Work Names Horizon Therapeutics plc to Best Workplaces for Parents List
Dec 1, 2021 01:30AM Horizon Therapeutics plc Provides Academic Scholarships to Help Economically Disadvantaged Students in Ireland Further Their STEM Education
Nov 22, 2021 08:06AM Horizon Therapeutics (HZNP) Announces Publication of New Analysis Supporting Efficacy of UPLIZNA
Nov 22, 2021 08:00AM New Analysis Published in Multiple Sclerosis and Related Disorders Supports the Efficacy of UPLIZNA® (inebilizumab-cdon) in Patients Previously Treated with Rituximab for Neuromyelitis Optica Spectru
Nov 15, 2021 09:00AM Horizon Therapeutics Recognizes Second Annual Thyroid Eye Disease (TED) Awareness Week with New Educational and Community Building Initiative
Nov 12, 2021 08:34AM Horizon Therapeutics (HZNP) Reports Real-World Data Showing High Rate of Patient Adherence to TEPEZZA for Thyroid Eye Disease
Nov 12, 2021 08:33AM New Real-World Data Show High Rate of Patient Adherence to TEPEZZA® (teprotumumab-trbw) for Thyroid Eye Disease (TED)
Nov 12, 2021 07:30AM Horizon Therapeutics (HZNP) Receives CHMP Positive Opinion for UPLIZNA as Monotherapy for Treatment of Adult Patients with Neuromyelitis Optica Spectrum Disorder
Nov 12, 2021 07:29AM Horizon Therapeutics plc Receives CHMP Positive Opinion for UPLIZNA® (inebilizumab) as a Monotherapy for the Treatment of Adult Patients with Neuromyelitis Optica Spectrum Disorder (NMOSD)
Nov 9, 2021 08:00AM Horizon Therapeutics plc Announces First Patient Enrolled in Phase 2b Pivotal Trial Evaluating HZN-825 for the Treatment of Diffuse Cutaneous Systemic Sclerosis
Nov 8, 2021 04:05PM Horizon Therapeutics plc to Participate in Upcoming Investor Conferences
Nov 5, 2021 09:01AM Horizon Therapeutics plc Receives Top Workplace Awards in Chicago and San Francisco
Nov 4, 2021 01:00PM Results from PROTECT Trial Evaluating KRYSTEXXA® (pegloticase injection) in Kidney Transplant Recipients with Uncontrolled Gout Presented as Part of American Society of Nephrology (ASN) Kidney Week
Nov 3, 2021 07:02AM Horizon Therapeutics (HZNP) Announces CFO Steps Down, Aaron Cox Names as Successor
Nov 3, 2021 07:02AM Horizon Therapeutics plc Announces Chief Financial Officer Succession Plan
Nov 3, 2021 07:00AM Horizon Therapeutics plc Reports Record Third-Quarter 2021 Financial Results; Increasing Full-Year 2021 Net Sales and Adjusted EBITDA Guidance
Nov 1, 2021 10:00AM New Data Being Presented at American College of Rheumatology Convergence 2021 Highlight Horizon’s Commitment to Improving Outcomes for People Living with Uncontrolled Gout
Oct 25, 2021 08:04AM Horizon Therapeutics (HZNP) Announces MIRROR Randomized Controlled Trial Meets Primary Endpoint and Shows 71% of Patients Achieved a Complete Response Rate Using KRYSTEXXA with Methotrexate
Oct 25, 2021 08:00AM MIRROR Randomized Controlled Trial Meets Primary Endpoint and Shows 71% of Patients Achieved a Complete Response Rate Using KRYSTEXXA® (pegloticase injection) with Methotrexate
Oct 22, 2021 09:29AM Horizon Therapeutics plc Named to Newsweek’s List of the Most Loved Workplaces for 2021
Oct 21, 2021 12:02PM Horizon Therapeutics (HZNP) Announces Newly Published Data Continue to Support Long-Term Efficacy of TEPEZZA® (teprotumumab-trbw) for Thyroid Eye Disease
Oct 21, 2021 12:00PM Newly Published Data Continue to Support Long-Term Efficacy of TEPEZZA® (teprotumumab-trbw) for Thyroid Eye Disease (TED)
Oct 13, 2021 08:00AM New Data Reinforce the Relationship Between B-Cell Depletion and Improved Outcomes in People Receiving UPLIZNA® (inebilizumab-cdon) for Neuromyelitis Optica Spectrum Disorder (NMOSD)
Oct 12, 2021 09:00AM New TEPEZZA® (teprotumumab-trbw) Data to be Presented at the American Academy of Ophthalmology (AAO) 2021 Annual Meeting
Oct 11, 2021 08:00AM Horizon Therapeutics plc to Release Third-Quarter 2021 Financial Results and Host Webcast on Nov. 3, 2021
Oct 6, 2021 08:00AM Horizon Therapeutics plc Named One of the 2021 Top 100 Adoption-Friendly Workplaces by the Dave Thomas Foundation for Adoption
Oct 4, 2021 08:34AM Horizon Therapeutics (HZNP) Announces New Analysis Published in Multiple Sclerosis Journal Assesses Long-Term Use of UPLIZNA for Treatment of NMOSD
Oct 4, 2021 08:30AM New Analysis Published in Multiple Sclerosis Journal Assesses Long-Term Use of UPLIZNA® (inebilizumab-cdon) for the Treatment of Neuromyelitis Optica Spectrum Disorder (NMOSD)
Oct 4, 2021 08:08AM Horizon Therapeutics (HZNP) Announces New UPLIZNA Data in Neuromyelitis Optica Spectrum Disorder (NMOSD)
Oct 4, 2021 08:00AM Horizon Therapeutics plc Announces New UPLIZNA® (inebilizumab-cdon) Data in Neuromyelitis Optica Spectrum Disorder (NMOSD) to be presented at ECTRIMS 2021
Sep 29, 2021 07:00AM Horizon Therapeutics plc Announces New Development Programs at Virtual R&D Day
Sep 23, 2021 09:00AM  Horizon Therapeutics plc Announces Agenda for Virtual R&D Day for Investors and Analysts on Sept. 29, 2021
Sep 23, 2021 08:30AM Horizon Therapeutics (HZNP) New Data Shows UPLIZNA Produces Rapid and Sustained B-Cell Depletion in African Americans with Neuromyelitis Optica Spectrum Disorder
Sep 23, 2021 08:30AM Horizon Therapeutics plc Announces Data Showing UPLIZNA® (inebilizumab-cdon) Also Produces Rapid and Sustained B-Cell Depletion in African Americans with Neuromyelitis Optica Spectrum Disorder (NMOSD
Sep 21, 2021 08:00AM Horizon Therapeutics plc Announces New Genetic Counselor Curated Algorithms and Next-Generation Sequencing Data as Winning Solutions of First-Ever Horizon Prize, Powered by MIT Solve, to Accelerate Ra
View More Recent Stories View Older Stories